标题：重组人干扰素α1b雾化吸入联合布地奈德治疗儿童反复上呼吸道感染的临床疗效及对免疫功能的影响

      作者：李青，梁宽，胡梦娇，赵静利，罗婷婷    宝鸡市人民医院儿科，陕西 宝鸡 721000

      卷次： 2023年34卷6期

      【摘要】 目的 观察重组人干扰素α1b雾化吸入联合布地奈德治疗儿童反复上呼吸道感染的疗效，并探讨期对患儿免疫功能的影响。方法 选取2018年10月至2021年10月宝鸡市人民医院收治的80例反复上呼吸道感染患儿为研究对象，采用随机数表法分为观察组和对照组各40例。对照组患儿给予匹多莫德治疗，观察组患儿给予重组人干扰素α1b雾化吸入联合布地奈德治疗，连续治疗4周。比较两组患儿的临床疗效、症状缓解时间以及治疗前后的体液免疫功能指标[IgA、IgG、IgM]，同时记录两组患儿用药期间的药物不良反应发生情况。结果 观察组患儿的治疗总有效率为92.50%，明显高于对照组的75.00%，差异有统计学意义(P<0.05)；治疗后，观察组患儿的持续发热消失时间、肺啰音消失时间、咳嗽消失时间、咽喉肿痛消失时间、复发次数及发病时间分别为(1.92±0.56) d、(4.45±1.37) d、(2.76±0.73) d、(2.61±0.71) d、(1.85±0.61)次、(6.92±1.27) d，明显短于对照组的(2.95±0.63) d、(6.61±0.98) d、(4.08±0.85) d、(3.97±0.78) d、(4.23±1.34)次、(7.58±1.33) d，差异均有统计学意义(P<0.05)；观察组患儿治疗后的 IgG、IgA及 IgM水平分别为(9.83±1.43) g/L、(1.89±0.41) g/L、(1.98±0.46) g/L，明显高于对照组的(8.62±1.41) g/L、(1.60±0.37) g/L、(1.73±0.42) g/L，差异均有统计学意义(P<0.05)；观察组和对照组患儿治疗期间的不良反应发生率分别为7.50%、2.50%，差异无统计学意义(P>0.05)。结论 重组人干扰素α1b雾化吸入联合布地奈德治疗儿童反复上呼吸道感染疗效较好，且有助于改善患儿的免疫功能。
      【关键词】 儿童；反复上呼吸道感染；布地奈德；重组人干扰素α1b；临床疗效；免疫功能
      【中图分类号】 R725.6 【文献标识码】 A 【文章编号】 1003—6350（2023）06—0818—04

Clinical curative effect of recombinant human interferon α1b for aerosol inhalation combined with budesonideon children with recurrent respiratory tract infections and its influences on immune function.
LI Qing, LIANGKuan, HU Meng-jiao, ZHAO Jing-li, LUO Ting-ting. Department of Pediatrics, Baoji People's Hospital, Baoji 721000,Shaanxi, CHINA
【Abstract】 Objective To explore the curative effect of recombinant human interferon α1b for aerosol inhala-tion combined with budesonide on children with recurrent respiratory tract infections (RRTIs) and its influences on im-mune function. Methods A total of 80 children with RRTIs admitted to Baoji People's Hospital were enrolled as the re-search objects between October 2018 and October 2021. According to random number table method, they were dividedinto an observation group and a control group, with 40 patients in each group. The control group was given pidotimod,while the observation group was given recombinant human interferon α 1b for aerosol inhalation combined withbudesonide, both continuously for 4 weeks. The clinical curative effect, remission time of symptoms, and levels of hu-moral immune function indexes (IgA, IgG, IgM) in the two groups were compared before and after treatment. The oc-currence of adverse drug reactions during medication in both groups was recorded. Results The total response rate oftreatment in the observation group was significantly higher than that in the control group (92.50% vs 75.00%, P<0.05).The disappearance time of sustained fever, lung rales, cough and sore throat, times of recurrence, and duration of on-sets in the observation group were (1.92±0.56) d, (4.45±1.37) d, (2.76±0.73) d, (2.61±0.71) d, (1.85±0.61) times, and(6.92±1.27) d, significantly shorter than (2.95±0.63) d, (6.61±0.98) d, (4.08±0.85) d, (3.97±0.78) d, (4.23±1.34) times,(7.58±1.33) d in the control group (P<0.05). After treatment, levels of IgG, IgA, and IgM in the observation groupwere (9.83±1.43) g/L, (1.89±0.41) g/L, and (1.98±0.46) g/L, significantly higher than (8.62±1.41) g/L, (1.60±0.37) g/L,(1.73±0.42) g/L in the control group (P<0.05). There was no significant difference in the incidence of adverse reactionsbetween observation group and control group during treatment (7.50% vs 2.50%, P>0.05). Conclusion The curative ef-fect of recombinant human interferon α1b for aerosol inhalation combined with budesonide is relatively better on chil-dren with RRTIs, which is beneficial to improve their immune function.
      【Key words】 Children; Recurrent respiratory tract infection; Budesonide; Recombinant human interferon α1b;Curative effect; Immune function